吉西他濱與胰腺癌化療耐藥_《中國普外基礎與臨床雜志》

作者：

潘博 , 郭俊超 , 廖泉 , 趙玉沛

中國醫學科學院中國協和醫科大學北京協和醫院基本外科（北京100731）;;
通訊作者：郭俊超;

關鍵詞：

胰腺癌化療吉西他濱耐藥性

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

【摘要】目的探討胰腺癌對吉西他濱化療產生耐藥性的相關機理。
方法復習近年國、內外相關文獻，對介導胰腺癌吉西他濱耐藥性的主要基因及信號通路加以綜述。
結果癌基因c-Src與bcl-XL、NF-κB炎癥信號通路、細胞因子IL-1β及NO等與介導胰腺癌對吉西他濱的耐藥性密切相關；多藥耐藥基因MDR1/PgP與胰腺癌吉西他濱耐藥的相關性仍有待研究。
結論癌基因c-Src與bcl-XL、NF-κB炎癥信號通路等可能成為新的治療靶點以增加胰腺癌的化療敏感性；介導胰腺癌化療耐藥的關鍵基因與中心信號通路尚有待闡明。

引用本文： 潘博,郭俊超,廖泉,趙玉沛. 吉西他濱與胰腺癌化療耐藥. 中國普外基礎與臨床雜志, 2005, 12(5): 530-532. doi: 復制

1.	Li D, Xie K, Wolff R, et al. Pancreatic cancer [J]. Lancet， 2004； 363(9414)∶1049.
2.	郭俊超, 趙玉沛. 多藥耐藥基因與胰腺癌化療 [J]. 胰腺病學， 2002； 2(4)∶247.
3.	Abrams RA. Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶3.
4.	Hochster HS. Newer approaches to gemcitabinebased therapy of pancreatic cancer: fixeddoserate infusion and novel agents [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶24.
5.	Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5Fluorouracil and gemcitabine is associated with altered expression of apoptosisregulating genes [J]. Oncology， 2002； 62(4)∶354.
6.	Duxbury MS, Ito H, Zinner MJ, et al. siRNA directed against cSrc enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity [J]. J Am Coll Surg, 2004； 198(6)∶953.
7.	Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondriamediated apoptosis [J]. Int J Cancer, 2004； 109(2)∶182.
8.	Plath T, Peters M, Detjen K, et al. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapyinduced apoptosis [J]. J Natl Cancer Inst, 2002； 94(2)∶129.
9.	Fahy BN, Schlieman MG, Virudachalam S, et al. Inhibition of AKT abrogates chemotherapyinduced NFkappaB survival mechanisms: implications for therapy in pancreatic cancer [J]. J Am Coll Surg, 2004； 198(4)∶591.
10.	Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death [J]. Oncogene, 2003； 22(21)∶3243.
11.	Muerkoster S, Arlt A, Witt M, et al. Usage of the NFkappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003； 104(4)∶469.
12.	Muerkoster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin1beta [J]. Cancer Res, 2004； 64(4)∶1331.
13.	Togawa A, Ito H, Kimura F, et al. Establishment of gemcitabineresistant human pancreatic cancer cells and effect of brefeldina on the resistant cell line [J]. Pancreas, 2003； 27(3)∶220.
14.	李驥. 胰腺癌和腫瘤多藥耐藥 [J]. 國外醫學外科學分冊， 2004； 31(2)∶69.
15.	Zhao YP, Zhang LY, Liao Q, et al. Detection of multidrug resistant gene 1 in pancreatic cancer [J]. Hepatobiliary Pancreat Dis Int, 2004； 3(2)∶307.
16.	Miller DW, Fontain M, Kolar C, et al. The expression of multidrug resistanceassociated protein (MRP) in pancreatic adenocarcinoma cell lines [J]. Cancer Lett, 1996； 107(2)∶301.

1. Li D, Xie K, Wolff R, et al. Pancreatic cancer [J]. Lancet， 2004； 363(9414)∶1049.
2. 郭俊超, 趙玉沛. 多藥耐藥基因與胰腺癌化療 [J]. 胰腺病學， 2002； 2(4)∶247.
3. Abrams RA. Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶3.
4. Hochster HS. Newer approaches to gemcitabinebased therapy of pancreatic cancer: fixeddoserate infusion and novel agents [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶24.
5. Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5Fluorouracil and gemcitabine is associated with altered expression of apoptosisregulating genes [J]. Oncology， 2002； 62(4)∶354.
6. Duxbury MS, Ito H, Zinner MJ, et al. siRNA directed against cSrc enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity [J]. J Am Coll Surg, 2004； 198(6)∶953.
7. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondriamediated apoptosis [J]. Int J Cancer, 2004； 109(2)∶182.
8. Plath T, Peters M, Detjen K, et al. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapyinduced apoptosis [J]. J Natl Cancer Inst, 2002； 94(2)∶129.
9. Fahy BN, Schlieman MG, Virudachalam S, et al. Inhibition of AKT abrogates chemotherapyinduced NFkappaB survival mechanisms: implications for therapy in pancreatic cancer [J]. J Am Coll Surg, 2004； 198(4)∶591.
10. Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death [J]. Oncogene, 2003； 22(21)∶3243.
11. Muerkoster S, Arlt A, Witt M, et al. Usage of the NFkappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003； 104(4)∶469.
12. Muerkoster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin1beta [J]. Cancer Res, 2004； 64(4)∶1331.
13. Togawa A, Ito H, Kimura F, et al. Establishment of gemcitabineresistant human pancreatic cancer cells and effect of brefeldina on the resistant cell line [J]. Pancreas, 2003； 27(3)∶220.
14. 李驥. 胰腺癌和腫瘤多藥耐藥 [J]. 國外醫學外科學分冊， 2004； 31(2)∶69.
15. Zhao YP, Zhang LY, Liao Q, et al. Detection of multidrug resistant gene 1 in pancreatic cancer [J]. Hepatobiliary Pancreat Dis Int, 2004； 3(2)∶307.
16. Miller DW, Fontain M, Kolar C, et al. The expression of multidrug resistanceassociated protein (MRP) in pancreatic adenocarcinoma cell lines [J]. Cancer Lett, 1996； 107(2)∶301.

《中國普外基礎與臨床雜志》

吉西他濱與胰腺癌化療耐藥

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

吉西他濱與胰腺癌化療耐藥

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料